People may need another booster dose in fall of 2022: Moderna CEO Bancel

The efficacy of boosters against COVID-19 is likely to decline over the next few months and people may need another shot in the fall of 2022, Moderna CEO said

moderna, covid, vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Reuters
1 min read Last Updated : Jan 07 2022 | 8:37 AM IST
The efficacy of boosters against COVID-19 is likely to decline over the next few months and people may need another shot in the fall of 2022, Moderna Inc Chief Executive Officer Stephane Bancel said at a Goldman Sachs-organized healthcare conference on Thursday.

Bancel said the company is working on a vaccine candidate tailored to the Omicron variant of the coronavirus, but is unlikely to be available in the next two months.

"I still believe we're going to need boosters in the fall of '22 and forward," Bancel said.

His comments on needing a fourth shot come on the back of Israeli Prime Minister Naftali Bennett citing a study on Tuesday that a fourth dose of COVID-19 vaccine boosts antibodies five-fold a week after the shot is administered.

Moderna, which benefits by repeat inoculations, during its third quarter earnings results said commercial booster market sales could be up to $2 billion in the United States in 2022.
(Reporting by Leroy Leo; Editing by Shailesh Kuber)

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccinehealth

Next Story